GleamWall
中文EN

CKDXF Opthea Ltd IFRS Annual reports only

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1815620 · Fiscal year ends 06/30

Financial factors as of 2023-06-30 (FY2023), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY19.1%
TTM net income YoY-53.5%
TTM EPS YoY-22.0%
Revenue 3-yr CAGR22.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-138,912.0%
Net margin-131,963.9%
FCF margin-111,694.4%
EBITDA margin-138,896.3%

Returns

ROE-676.7%
ROA-179.6%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets105.9%
Debt / equity—
Current ratio5.25x
Interest coverage-11.14x

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-27.6%
Payout ratio—
Capex / revenue20.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-06-30FY20242024-06-30
Income statement
Revenue$25,000$125,000
R&D expense$126.83M$176.33M
Operating income-$155.76M-$191.84M
Interest expense$46.46M$30.26M
Pretax income-$169.74M-$229.65M
Income tax-$6.95M-$9.41M
Net income-$162.79M-$220.24M
EBITDA-$155.75M-$191.82M
EPS (basic)-0.13-0.35
EPS (diluted)-0.13-0.35
Weighted avg. shares (diluted)1.22B638.20M
Balance sheet
Cash & equivalents$48.44M$172.47M
Receivables$419,000$1.43M
Current assets$56.80M$188.19M
PP&E, netmay include right-of-use assets (IFRS)$0$48,000
Total assets$56.80M$188.79M
Current liabilities$257.87M$64.06M
Short-term debt$9.74M$38.06M
Total liabilities$257.87M$264.60M
Shareholders' equity-$201.07M-$75.81M
Cash flow statement
Operating cash flow-$158.64M-$161.01M
Capital expenditure$13,000$33,000
Free cash flow-$158.66M-$161.05M
Investing cash flow-$13,000-$33,000
Financing cash flow$34.77M$243.73M
Depreciation & amortization$7,000$19,000
Stock-based compensation$6.13M$5.08M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.